InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Indian patentability refined, post-Glivec

The Novartis decision on April 1 2013 turned the spotlight on section 3(d) of India’s Patent Act. A year on, Meenakshi Khurana looks at how this doctrine, along with obviousness standards, have been interpreted in recent cases

Though section 3(d), which bars patentability of a new form of a known compound unless the applicant shows enhanced therapeutic efficacy, and the Novartis case have been emblematic of India's tough patent system, there is another important trend at play....

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog

null null null

null null null


September / October 2019

Should I stay or should I go? Private practice v in-house

In-house or private practice? It’s a question many lawyers and attorneys will probably ask themselves at some stage in their career, as Managing IP finds out

Most read articles